Abstract
Genetic and genomic technologies have facilitated a greater understanding of the Tasmanian devil immune system and the origins, evolution and spread of devil facial tumour disease (DFTD). DFTD is a contagious cancer that has caused significant declines in devil populations across Tasmania. Immune responses to DFTD are rarely detected, allowing the cancer to pass between individuals and proliferate unimpeded. Early immunosenscence in devils appears to decrease anti-tumour immunity in older animals compared to younger animals, which may increase susceptibility to DFTD and explain high DFTD prevalence in this age group. Devils also have extremely low major histocompatibility complex (MHC) diversity, and multiple alleles are shared with the tumour, lowering histocompatibility barriers which may have contributed to DFTD evolution. DFTD actively evades immune attack by down-regulating cell-surface MHC I molecules, making it effectively invisible to the immune system. Altered MHC I profiles should activate natural killer (NK) cell anti-tumour responses, but these are absent in DFTD infection. Recent immunisation and immunotherapy using modified DFTD cells has induced an anti-DFTD immune response and regression of DFTD in some devils. Knowledge gained from immune responses to a transmissible cancer in devils will ultimately reveal useful insights into immunity to cancer in humans and other species.
Similar content being viewed by others
References
Bjorkman PJ (1990) Structure, function and diversityof class I major histocompatability complex molecules. Annu Rev Biochem 59:254–288
Bradshaw CJA, Brook BW (2005) Disease and the devil: density-dependent epidemiological processes explain historical population fluctuations in the Tasmanian devil. Ecography 28:181–190
Brown OJF (2006) Tasmanian devil (Sarcophilus harrisii) extinction on the Australian mainland in the mid-Holocene: multicausality and ENSO intensification. Alcheringa 30:49–57
Brown GK, Kreiss A, Lyons AB, Woods GM (2011) Natural killer cell mediated cytotoxic responses in the Tasmanian devil. PLoS ONE 6:1–10
Brown GK et al (2016) Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells. Immunol Cell Biol 94:673–679
Bruniche-Olsen A, Jones ME, Austin JJ, Burridge CP, Holland BR (2014) Extensive population decline in the Tasmanian devil predates European settlement and devil facial tumour disease. Biol Lett 10:20140619
Carson WE et al (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31:3016–3025
Cheng Y, Belov K (2014) Characterisation of non-classical MHC class I genes in the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 66:727–735. https://doi.org/10.1007/s00251-014-0804-3
Cheng Y, Sanderson CE, Jones M, Belov K (2012a) Low MHC class II diversity in the Tasmanian devil. Immunogenetics 64:525–533
Cheng Y et al (2012b) Antigen-presenting genes and genomic copy number variations in the Tasmanian devil MHC. BMC Genom 13:87
Cheng Y et al (2017) Significant decline in anticancer immune capacity during puberty in the Tasmanian devil. Sci Rep 7:e44716
Coffelt SB, de Visser KE (2015) Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol 36:198–216
Cui J, Cheng Y, Belov K (2015) Diversity in the Toll-like receptor genes of the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 67:195–201. https://doi.org/10.1007/s00251-014-0823-0
Dajon M, Iribarren K, Cremer I (2017) Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword. Immunobiology 222:89–100
Ethier J, Desautels D, Templeton A, Shah PS, Amir E (2017) Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 19:2
Flies AS et al (2016) PD-L1 is not constitutively expressed on Tasmanian devil facial tumour cells but is strongly upregulated in response to IFN-gamma and can be expressed in the tumour microenvironment. Front Immunol 7:581
Ganguly B, Das U, Das AK (2016) Canine transmissible venereal tumour: a review. Vet Comp Oncol 14:1–12. https://doi.org/10.1111/vco.12060
Gu X et al (2016) Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci Rep 6:22089
Guthrie GJK, Charles KA, Roxburhgh CSD, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88:218–230
Hamede R, McCallum H, Jones M (2013) Biting injuries and transmission of Tasmanian devil facial tumour disease. J Anim Ecol 82:182–190
Hawkins CE et al (2006) Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii. Biol Conserv 131:307–324
Haynes JI (2001) The marsupial and monotreme thymus revisited. J Zool 253:167–173
Howson LJ et al (2014) Identification of dendritic cells, B cell and T cell subsets in Tasmanian devil lymphoid tissue; evidence of poor immune cell infiltration into devil facial tumours. Anat Rec 297:925–938
Hubbard G, Saphire D, Hackleman S, Silva M, Vandeberg JL, Stone W (1991) Ontogeny of the thymus gland of a marsupial (Monodelphis domestica). Lab Anim Sci 41:227–232
Jones ME, Paetkau D, Geffen E, Moritz C (2004) Genetic diversity and population structure of Tasmanian devils, the largest marsupial carnivore. Mol Ecol 13:2197–2209
Jones ME et al (2008) Life history change in disease-ravaged Tasmanian devil populations. Proc Natl Acad Sci 105:10023–10027
Jones EA, Cheng Y, O’Meally D, Belov K (2017) Characterisation of the antimicrobial peptide family defensins in the Tasmanian devil (Sarocphilus harrisii), koala (Phascolarctos cinereus), and tammar wallaby (Macropus eugenii). Immunogenetics 69:133–143
Keaney MA, Hirte H, McPhail S, Fernando L, Belanger R, Richter M (1979) The antibody-dependent cell-mediated cytotoxic reaction I the morphological functional heterogeneity of the rabbot cytotoxic cells. Immunology 38:665–676
Kreiss A, GFox N, Bergfield J, Quinn SJ, Pyecroft S, Woods GM (2008) Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii). Dev Comp Immunol 32:544–553
Kreiss A, Cheng Y, Kimble F, Wells B, Donovan S, Belov K, Woods GM (2011) Allogrecogniion in the Tasmanian devil (Sarocphilus harrisii), an endangered marsupial species with limited genetic diversity. PLoS ONE 6:e22402
Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM (2015) Evidence for induction of humoral and cytotoxic immune responses against devil facial tumour disease cels in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations. Vaccine 33:3016–3025
Loh R, Bergfield J, Hayes D, O’Hara A, Pyecroft S, Raidal S, R S (2006a) The pathology of Devil facial tumor disease (DFTD) in Tasmanian devils (Sarcophilus harrisii). Vet Pathol 43:890–895
Loh R, Hayes D, Mahjoor A, O’Hara A, Pyecroft S, Raidal S (2006b) The immunohistochemical characterization of Devil facial tumor disease (DFTD) in the Tasmanian devil (Sarcophilus harrisii). Vet Pathol 43:896–903
Manley NR, Blackburn ERR, Condie CC, Sage BR J (2011) Strucure and function of the thymic microenvironment. Front Biosci 16:2461–2477
McCallum H et al (2009) Transmission dynamics of Tasmanian devil facial tumor disease may lead to disease-induced extinction. Ecology 90:3379–3392. https://doi.org/10.2307/25660985
Metzger MJ, Reinisch C, Sherry J, Goff SP (2015) Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams. Cell 161:255–263
Metzger MJ et al (2016) Widespread transmission of independent cancer lineages within multiple bivalve species. Nature 534:705–709
Morris K, Belov K (2013) Does the devil facial tumour produce immunosuppressive cytokines as an immune evasion strategy? Vet Immunol Immunopathol 153:159–164
Morris B, Cheng Y, Warren W, Papenfuss AT, Belov K (2015) Identification and analysis of divergent immune gene families within the Tasmanian devil genome. BMC Genom 16:1017
Murchison EP et al (2010) The Tasmanian devil transcriptome reveals schwann cell origins in a clonally transmissible cancer. Science 327:84–87
Murchison EP et al (2012) Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell 148:780–791
Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA (2006) Clonal origin and evolution of a transmissible cancer. Cell 126:477–487
Owen D, Pemberton D (2005) Tasmanian devil: a unique and threatened animal. Allen & Unwin, Sydney
Paddle R (2000) The last Tasmanian tiger: the history and extinction of the thylacine. Cambridge University Press, Cambridge
Pahl J, Cerwenka A (2017) Tricking the balance: NK cells in anti-cancer immunity. Immunobiology 222:11–20
Patchett AL, Latham R, Brettingham-Moore KH, Tovar C, Lyons AB, Woods GM (2015) Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil. Dev Comp Immunol 53:123–133
Patchett AL, Tovar C, Corcoran LM, Lyons AB, Woods GM (2017) The toll-like receptor ligands Hiltonol (polyICLC) and imiquimod effectively activate antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii). Dev Comp Immunol 76:352–360
Pearse AM, Swift K (2006) Transmission of devil facial-tumour disease. Nature 439:549
Peck S, Corkrey R, Hamede R, Jones M, Canfield P (2016) Hematologic and serum biochemical changes associated with devil facial tumour disease in Tasmanian devils. Vet Clin Pathol 45:417–429
Peel E, Belov K (2017) Immune-endocrine interactions in marsupials and monotremes. Gen Comp Endocrinol 244:178–185
Peel E, Cheng Y, Djordjevic JT, Fox S, Sorrell TC, Belov K (2016) Cathelicidins in the Tasmanian devil (Sarcophilus harrisii). Sci Rep 6:e35019
Perez-de-Heredia F et al (2015) Influence of sex, age, pubertal maturation and body mass index on circulating white blood cell counts in healthy european adolescents - the HELENA study. Eur J Pediatr 174:999–1014
Pye E et al (2016a) Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils. Biol Lett. https://doi.org/10.1098/rsbl.2016.0553
Pye RJ et al (2016b) A second transmissible cancer in Tasmanian devils. Proc Natl Acad Sci 113:374–379
Pye RJ, Woods GM, Kreiss A (2016c) Devil facial tumour disease. Vet Pathol 53:726–736
Pye R et al (2018) Immunization strategies producing a humoral IgG immune response against devil facial tumour disease in the majority of Tasmanian devils destined for wild release. Front Immunol 9:259
Pyecroft SB et al (2007) Towards a case definition for devil facial tumour disease: what is it? EcoHealth 4:346–351
Quattrocchi V, Pappalardo JS, Langellotti C, Smitsaart E, Fondevila N, Zamorano P (2014) Early protection against foot-and-mouth disease virus in cattle using an inactivated vaccine formulated with Montanide ESSAI IMS D 12802 VG PR adjuvant. Vaccine 32:2167–2172
Richers CD, Hoekstra MJ, du Pont JS, Kreis RW, Kamperdijk EWA (2003) Immunology of skin transplantation. Clin Dermatol 23:338–342
Save The Tasmanian Devil Program (2015) The disease. http://www.tassiedevil.com.au/tasdevil.nsf/Te-Disease/979FEB5F116CE371CA2576CB0011A26E. 2018
Schuurs AHWM, Verheul HAM (1990) Effects of gender and sex steroids on the immune response. J Steroid Biochem 35:157–172
Siddle HV et al (2007a) Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci 104:16221–16226
Siddle HV, Sanderson CE, Belov K (2007b) Characterization of major histocompatability complex class I and II genes from the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 59:753–760
Siddle HV, Marzec J, Chen Y, Jones M, Belov K (2010) MHC gene copy number variation in Tasmanian devils: implications for the spread of a contagious cancer. Proc R Soc B 277:2001–2006
Siddle HV et al (2013) Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc Natl Acad Sci 110:5103–5108
Stockmeyer B, Beyer T, Neuhuber W, Repp R, Kalden JR, Valerius T, Herrmann M (2003) Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol 171:5124–5129
Templeton AJ et al (2014) Progostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systemic review and meta-analysis. J Natl Cancer Inst 106:dju124
Tovar C, Obendorf DL, Murchison EP, Papenfuss AT, Kreiss A, Woods GM (2011) Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils immunohistochemistry studies. Vet Pathol 48:1195–1203
Tovar C et al (2017) Regression of devil facial tuomur disease following immunotherapy in immunised Tasmanian devils. Sci Rep 7:e43827
Uesaka T et al (2007) Expression of VEGF and its receptor genes in intracranial schwannomas. J Neuro-Oncol 83:259–266
Ujvari B et al (2012) Telomere dynamics and homeostasis in a transmissible cancer. PLoS ONE 7:e44085
Ujvari B et al (2014) Anthropogenic selection enhances cancer evolution in Tasmanian devil tumours. Evol Appl 7:260–265
Ujvari B, Gatenby RA, Thomas F (2016) The evolutionary ecology of transmissible cancers Infection. Genet Evol 39:293–303
Valmori D et al (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci 104:8947–8952
van der Kraan LE, Wong ESW, Lo N, Ujvari B, Belov K (2013) Identification of natural killer cell receptor genes in the genome of the marsupial Tasmanian devil (Sarcophilus harrisii). Immunogenetics 65:25–35
Verthelyi D (2001) Sex hormones as immunomodulators in health and disease. J Immunopharmacol 1:983–993
Wong ESW et al (2011) Transcriptomic analysis supports similar functional roles for the two thymuses of the tammar wallaby. BMC Genom 12:1–12
Woods GM, Kreiss A, Belov K, Siddle HV, Obendorf DL, Muller HK (2007) The immune response of the Tasmanian devil (Sarcophilus harrisii) and devil facial tumour disease. EcoHealth 4:338–345
Zitvogel L, Kroemer G (2012) Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1:1223–1225
Acknowledgements
Our work is supported by an Australian Research Council Discovery grant to KB. We thank current and former members of the lab and our collaborators for the significant contributions they have made to this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Rights and permissions
About this article
Cite this article
Peel, E., Belov, K. Lessons learnt from the Tasmanian devil facial tumour regarding immune function in cancer. Mamm Genome 29, 731–738 (2018). https://doi.org/10.1007/s00335-018-9782-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00335-018-9782-3